Comparative Pharmacology
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 10 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 10 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER.
COUMADIN vs HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits vitamin K epoxide reductase complex 1 (VKORC1), thereby decreasing the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.
Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing thrombus formation and propagation.
Initial dose 2-5 mg orally once daily, adjusted based on INR response; typical maintenance dose 2-10 mg/day.
IV: Initial bolus of 5000 units followed by continuous infusion at 1300 units/hour, adjusted based on aPTT. Typical infusion range 1000-2000 units/hour.
None Documented
None Documented
Terminal elimination half-life: 20–60 hours (mean ~40 hours); clinically, anticoagulant effect persists for 2–5 days after stopping due to hepatic synthesis of functional clotting factors.
30-60 minutes at therapeutic doses, dose-dependent (e.g., 100 U/kg yields t½ ~56 min; 400 U/kg yields ~152 min). At lower doses (e.g., 25 U/kg), t½ is ~30 min. Prolonged in hepatic or renal impairment.
Renal (approximately 92% as inactive metabolites), fecal/biliary (minor, approximately 8%). Less than 2% excreted unchanged.
Primarily renal; metabolism by hepatic and reticuloendothelial system desulfation yields uroheparin, which is excreted in urine. Unchanged heparin is also excreted renally, with elimination proportional to dose and molecular weight. Biliary/fecal excretion is negligible (<5%).
Category C
Category A/B
Anticoagulant
Anticoagulant